Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CS-7017 + paclitaxel
- Development stage
- Phase 2
- Lead developer
- Daiichi Sankyo
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
CS-7017 + paclitaxel is a combination investigational therapy consisting of CS-7017 (efatutazone), a selective agonist of peroxisome proliferator-activated receptor gamma (PPARγ), and paclitaxel, a widely used microtubule inhibitor chemotherapeutic agent. CS-7017 is a thiazolidinedione class synthetic ligand that regulates transcription involved in cellular energy metabolism, while paclitaxel inhibits cell mitosis and induces apoptosis by stabilizing microtubules. The combination has been investigated primarily in patients with advanced or metastatic anaplastic thyroid carcinoma and metastatic non-small cell lung cancer, based on evidence suggesting that CS-7017 enhances the pro-apoptotic effects of paclitaxel, potentially improving outcomes over single-agent therapy. Clinical studies demonstrated tolerability and initial biologic activity, with dose-dependent improvements in time to progression and survival, but the therapy remains investigational[1][7][5][6].
- Other names
- CS7017 + paclitaxelefatutazone + paclitaxel
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on CS-7017 + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CS-7017 + paclitaxel.